Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Hyrimoz“
Suchtreffer
Begriffe & Kennungen
Hyrimoz · 4.8 · In controlled Phase 3 studies of adalimumab in patients with polyarticular juvenile idiopathic arthritis who w
Eintrag öffnenHyrimoz · 4.8 · In controlled Phase 3 studies of adalimumab in patients with polyarticular juvenile idiopathic arthritis who w
Eintrag öffnenHyrimoz · 4.8 · In controlled Phase 3 studies of adalimumab in patients with rheumatoid arthritis and psoriatic arthritis with
Eintrag öffnenHyrimoz · 4.8 · In controlled Phase 3 studies of adalimumab in patients with rheumatoid arthritis and psoriatic arthritis with
Eintrag öffnenHyrimoz · 4.8 · In controlled and open label adult and paediatric studies with adalimumab, serious infections (including fatal
Eintrag öffnenHyrimoz · 4.8 · In controlled and open label adult and paediatric studies with adalimumab, serious infections (including fatal
Eintrag öffnenHyrimoz · 4.8 · In controlled studies of adalimumab (initial doses of 160 mg at Week 0 and 80 mg at Week 2, followed by 40 mg
Eintrag öffnenHyrimoz · 4.8 · In controlled studies of adalimumab (initial doses of 160 mg at Week 0 and 80 mg at Week 2, followed by 40 mg
Eintrag öffnenHyrimoz · 4.8 · In controlled studies of adalimumab (initial doses of 80 mg at Week 0 followed by 40 mg every other week start
Eintrag öffnenHyrimoz · 4.8 · In controlled studies of adalimumab (initial doses of 80 mg at Week 0 followed by 40 mg every other week start
Eintrag öffnenHyrimoz · 4.8 · In general, the adverse events in paediatric patients were similar in frequency and type to those seen in adul
Eintrag öffnenHyrimoz · 4.8 · In general, the adverse events in paediatric patients were similar in frequency and type to those seen in adul
Eintrag öffnenHyrimoz · 4.8 · In post-marketing experience from January 2003 to December 2010, predominantly in patients with rheumatoid art
Eintrag öffnenHyrimoz · 4.8 · In post-marketing experience from January 2003 to December 2010, predominantly in patients with rheumatoid art
Eintrag öffnenHyrimoz · 4.8 · In the Phase 3 study of adalimumab in patients with paediatric Crohn’s disease which evaluated efficacy and sa
Eintrag öffnenHyrimoz · 4.8 · In the Phase 3 study of adalimumab in patients with paediatric Crohn’s disease which evaluated efficacy and sa
Eintrag öffnenHyrimoz · 4.8 · In the controlled Phase 3 study of adalimumab in patients with paediatric ulcerative colitis (N=93) which eval
Eintrag öffnenHyrimoz · 4.8 · In the controlled Phase 3 study of adalimumab in patients with paediatric ulcerative colitis (N=93) which eval
Eintrag öffnenHyrimoz · 4.8 · In the pivotal controlled studies in adults and children, 12.9 % of patients treated with adalimumab developed
Eintrag öffnenHyrimoz · 4.8 · In the pivotal controlled studies in adults and children, 12.9 % of patients treated with adalimumab developed
Eintrag öffnen